Breaking Through Biases in Obesity Management: Building Competence, Creating Connections, and Empowering Leaders in Primary Care

Chair, Angela Fitch, MD, FACP, FOMA, Jaime Almandoz, MD, MBA, FTOS, and Carolynn Francavilla, MD, DABOM, FOMA, prepared useful Practice Aids pertaining to obesity for this CME/NCPD/AAPA activity titled “Breaking Through Biases in Obesity Management: Building Competence, Creating Connections, and Empowering Leaders in Primary Care.” For the full presentation, downloadable Practice Aids, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at https://bit.ly/3YYA4bF. CME/NCPD/AAPA credit will be available until March 10, 2026.

1. Starting the Process: Practical Steps
for Primary Care and Specialty Care Settings
a

Full abbreviations, accreditation, and disclosure information available at PeerView.com/SJY40
a
Specialty care settings include general neurology, geriatric psychiatry, and geriatrics (other than dementia subspecialty settings). Step 1
Step 2
Step 3
Step 4
Step 5
Diagnostic workup to confirm clinical diagnosis of MCI or mild
dementia due to AD (eg, medical history, risk factors, physical and
neurological exams; cognitive, functional, and behavioral assessments)
Order lab work and MRI to rule out non-AD etiologies and confirm
there are no contraindications to ATTs
Disclose suspected diagnosis, educate about ATTs and biomarker
testing, and assess interest in ATTs
If patient is interested in ATTs:
Order biomarker testing
if feasible
Refer to dementia specialist
for treatment
Refer to dementia specialist
for biomarker testing
and treatment
OR

2. Patient Education for Alzheimer?s Disease Biomarker Testing
1,2
Full abbreviations, accreditation, and disclosure information available at PeerView.com/SJY40 Printable Resource
1. AGREEDementia.org. https://cf0a52d991.clvaw-cdnwnd.com/9e9d33a0baaf7e6f666a2136d82e2828/200000133-e5668e566b/AGREED-Dementia-Group-Educational-Tool-Blood-Tests.pdf?ph=cf0a52d991.
2. VandeVrede L, Schindler SE. Alzheimers Dement. 2025;21:e14201.
Fluid and imaging biomarkers play key roles in the assessment
of Alzheimer’s disease pathology. This aid presents educational
resources to help patients understand the diferent biomarker tests
available to them and what their results might mean for them.
Clinicians are encouraged to download and use this education
as an aid in their clinical practice.

3. Access the AGREEDementia Decision Guides by Scanning the QR Codes

4. Q


A










  ­€
‚
Q

A



Q

A


ƒ
 




 ‚

Q


A
€

„

5. SPIKES Protocol for AD/ADRD Diagnostic Disclosure
1

Full abbreviations, accreditation, and disclosure information available at PeerView.com/SJY40 1. O’Brien K et al. Alzheimers Dement. 2024;21:e14200.
S P I K E S
Set up
interview
Assess the
patient’s (and/or
care partner’s)
Perception
Obtain the
patient’s (and/or
care partner’s)
Invitation
Give Knowledge
and information
Address Emotions
with empathy
Strategy and
summary
• Physically set up
a private, quiet
space
• Verbally set up
the context and
goals for the visit
• Understand the patient’s
(and/or care partner’s)
understanding and
appreciation of their
symptoms
• Determine if their
perception of their
symptoms has changed
since the beginning of
the evaluation process
• Assess their knowledge
of causes of cognitive
decline
• Assess whether the
patient (and/or care
partner) would like to
know the cause of their
symptoms
• Understand what types
of information they do
or do not want to learn
(eg, diagnosis, stage,
prognosis)
• Assess the patient’s
emotional readiness to
receive the information
• Provide results
of testing with
empathy
• Disclose syndromic
diagnosis, etiologic
diagnosis, and
stage
• May also discuss
prognosis if desired
by patient and/or
care partner
• Invite questions
from patient and/or
care partner
• Acknowledge the
emotional impact
of the diagnosis
• Provide
opportunity for the
patient and care
partner to express
their emotions
• Offer support
• Provide a preview
of a management
plan aligned with
the patient’s and
care partner’s goals
and needs
• Discuss follow-up
plan
• Reassess
understanding
• Provide a verbal
and written
summary of the
most relevant
information

6. Clinically Available Blood Tests in the United States
Full abbreviations, accreditation, and disclosure information available at PeerView.com/SJY40 PrecivityAD, PrecivityAD2
IP-MS
Aβ42/40, age, apoE proteotype;
Aβ42/40, p-tau217
ALZpathDx
Simoa
p-tau217
Lumipulse
Immunoassay
p-tau217, Aβ42/40,
p-tau217/Aβ42
AD-Detect
IP-MS for Aβ42/40; immunoassay
for p-tau181 and p-tau217
Aβ42/40, p-tau181, p-tau217
CertuitAD
Immunoassay
p-tau217
LucentAD
Simoa
p-tau217